3 news items
Revolution Medicines Reports First Quarter 2024 Financial Results and Update on Corporate Progress
RVMD
8 May 24
This press release contains forward-looking statements within the meaning of the U.S. Private Securities Litigation Reform Act of 1995
Revolution Medicines Announces Publication on the Discovery of and Translational Research for RMC-6236, an Investigational RAS(ON) Multi-Selective Tri-Complex Inhibitor Designed to Block Full Spectrum of Oncogenic RAS(ON) Proteins
RVMD
9 Apr 24
. Private Securities Litigation Reform Act of 1995. Any statements in this press release that are not historical facts may be considered "forward
Revolution Medicines Announces Publications on the Discovery and Preclinical Profile of Representative of a New Class of RAS(ON) Multi-Selective Inhibitors Designed to Block Full Spectrum of Oncogenic RAS(ON) Proteins
RVMD
8 Apr 24
contains forward-looking statements within the meaning of the U.S. Private Securities Litigation Reform Act of 1995. Any statements in this press
- Prev
- 1
- Next